Faecal levels of calprotectin in systemic sclerosis are stable over time and are higher compared to primary Sjögren’s syndrome and rheumatoid arthritis by unknown
Andréasson et al. Arthritis Research & Therapy 2014, 16:R46
http://arthritis-research.com/content/16/1/R46RESEARCH ARTICLE Open AccessFaecal levels of calprotectin in systemic sclerosis
are stable over time and are higher compared to
primary Sjögren’s syndrome and rheumatoid
arthritis
Kristofer Andréasson1*, Tore Saxne1, Agneta Scheja1, Izabela Bartosik1, Thomas Mandl2 and Roger Hesselstrand1Abstract
Introduction: Faecal calprotectin (FC) has been proposed to be a biomarker of gastrointestinal (GI) disease in systemic
sclerosis (SSc). The purpose of this study was to extend cross-sectional observations and prospectively assess the
variability of FC over time in SSc patients. We also aimed to examine FC in relation to immunosuppressive therapy.
Finally we wanted to analyse FC in other rheumatic diseases to evaluate the specificity of FC for SSc GI disease.
Methods: FC was measured in consecutive patients with SSc, primary Sjögren’s syndrome (pSS), rheumatoid arthritis
(RA) and in healthy hospital workers. The intraindividual variability of FC in SSc was assessed with intra class correlation
(ICC) and κ statistics. Associations between FC and objective markers of GI disease and immunosuppressive medication
were investigated.
Results: FC was associated with micronutrient deficiency and GI pathology as assessed by cineradiography confirming
our previous results. FC showed only a limited intra-individual variation in SSc, ICC = 0.69 (95% confidence interval,
CI: 0.57-0.78) and κ = 0.64 (95% CI: 0.56-0.73). Generalised immunosuppression did not have any significant impact on
FC. FC was significantly higher in SSc patients compared to patients with pSS or RA as well as compared to healthy
subjects.
Conclusions: FC is a promising non-invasive biomarker for GI disease in SSc. In view of stable levels over time, FC could
be a useful marker when novel, more specific drugs targeting the GI tract in SSc will be introduced.Introduction
Faecal calprotectin (FC) is a validated non-invasive bio-
marker in inflammatory bowel disease (IBD) [1,2]. Recently,
we presented FC as a possible biomarker of gastrointestinal
(GI) disease in systemic sclerosis (SSc). In that cross-
sectional study, we showed significant correlations between
FC and objective markers of SSc GI disease, that is, cinera-
diography and micronutrient deficiency [3].
GI manifestations of SSc are common and a major
concern in this disease [4]. Recent studies have suggested
that 90% or more of SSc patients have GI complications* Correspondence: kristofer.andreasson@med.lu.se
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article, unless otherwise stated.and GI involvement is a recognised cause of SSc-related
death [5-9].
Symptomatic treatment of several GI manifestations of
SSc is available, but current treatment regimens are
insufficient [10,11]. One problem in developing or iden-
tifying new drugs in this field is the lack of both objec-
tive and feasible biomarkers to monitor SSc GI disease
over time [12].
Calprotectin, also known as s100A8/A9, MRP8/14 or
calgranulin A/B, is a heterodimer composed of two small
proteins. It constitutes a major (40% to 60%) part of the
cytosolic proteins in neutrophils and is also present in
other myeloid cells. Calprotectin is released from leuko-
cytes both upon activation and cell death and levels of FC
correlate to leukocyte influx in the GI lumen [13,14]. The
calprotectin heterodimer is a stable complex inert to deg-
radation in stool even when kept at room temperature forntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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in active IBD, but increased levels have been reported in
some other inflammatory pathologies in both the upper
and lower GI tract including gastric ulcer, GI cancer and
bacterial gastroenteritis, but notably not small intestinal
bacterial overgrowth [16,17]. Repeated testing of FC in
IBD has proven that the biomarker co-varies with disease
activity [18]. In the field of gastroenterology, FC is today a
recognised clinical tool to investigate patients with unspe-
cific bowel symptoms, to monitor IBD over time and to
evaluate response to different treatment regimens [1]. In
IBD, immunosuppressive therapy is often successful and
accompanied by a decrease in FC. In SSc however, im-
munosuppressive therapy has not been shown to modify
the course of the GI disease.
The primary aim of the present study was to extend our
cross-sectional study and prospectively assess the varia-
bility over time of FC in SSc patients. A second aim was
to monitor FC in relation to conventional immunosup-
pressive therapy in SSc. A third aim was to examine FC in
other rheumatic diseases, that is, rheumatoid arthritis
(RA) and primary Sjögren’s syndrome (pSS) in order to
evaluate the specificity of pathological FC testing for SSc
GI disease in a rheumatological setting. For comparison,
FC was also assessed in healthy hospital workers.
Methods
Patients
This study was conducted at the Rheumatology Clinic,
Skåne University Hospital, Sweden, which is a referral centre
for SSc [19]. All patients admitted to in-hospital care for
evaluation of SSc between September 2008 and February
2013, fulfilling the 1980 American College of Rheumatology
(ACR) criteria for SSc were invited to deliver a stool sample
for analysis of FC upon each visit to the clinic. Patients who
had FC measured at least twice during this time period were
included in the study.
Consecutive patients with pSS according to the American-
European Consensus Classification Criteria, [20] visiting the
outpatient Rheumatology Clinic, Skåne University Hospital
Malmö, between June and December 2012, were included in
the study and delivered a stool sample after their clinical visit.
Consecutive patients with RA, positive for rheumatoid
factor or anti-cyclic citrullinated peptide antibodies, awaiting
either initiation of anti-TNF-α-therapy or orthopaedic sur-
gery at the Rheumatology Clinic, Skåne University Hospital
Lund, were invited to participate in this study as a second
reference group to the SSc cohort.
Patients with a history of IBD, GI malignancy, diver-
ticulitis or alcohol abuse were excluded.
Finally, healthy hospital workers, not currently treated
with non-steroidal anti-inflammatory drugs (NSAIDs) or
proton pump inhibitors (PPI) were asked to participate
in this study.Clinical assessment
Sex and age at time of stool delivery were recorded for
all subjects.
From all SSc patients, the following data were collected:
disease duration (defined as years since debut of first non-
Raynaud’s manifestation), autoantibody profile and results
from cineradiography. This examination has been proposed
to be a core set variable in the clinical evaluation of the GI
tract in SSc [21]. Cineradiography reports were independently
categorised by RH and AS, who were blinded with regard to
patient data. Cineradiographies were analysed in reference to
motility. Investigations showing signs of disturbed motility
were regarded as pathological, and investigations with severe
dysfunction of the oesophagus, that is, aperistalsis, were clas-
sified as severely pathological. Investigations with no signs of
disturbed motility were regarded as normal. Investigations
were regarded as inconclusive if RH and AS did not both
agree that a cineradiography was normal or pathological.
When RH and AS disagreed on the severity of pathology, the
evaluation of the senior physician was chosen.
As we have previously studied FC in relation to the
modified Rodnan skin score, autoantibody status and
disease subtype without any associations identified, these
issues were not further investigated [3].
All pSS patients were categorised according to the
European League against Rheumatism (EULAR) Sjögren’s
Disease Activity Index (ESSDAI) and the Disease Activity
Score 28 based on C-reactive protein (CRP) and conse-
quently, and three variables (DAS28-CRP (3)) was calculated
for all RA patients [22,23].
Laboratory examinations
FC was measured in stool samples with a commercially
available ELISA using a monoclonal antibody (Bühlmann
Laboratories, Schönenbuch, Switzerland). The lower detec-
tion limit was 30 μg/g. Analyses were done at the Depart-
ment of Immunology, Skåne University Hospital, Lund.
Different cut-off levels of FC indicating organic disease
have been suggested. Two cut-off levels were used in this
study. Based on the majority of reports where the
current ELISA has been used, FC levels above 50 μg/g
were considered pathological [1,16,24]. Based on current
recommendations in Swedish practice, as well as inter-
national suggestions/experience, we also used a second
cut-off level of 200 μg/g to indicate substantial FC eleva-
tion [25,26].
All SSc patients were subject to analysis of the follow-
ing micronutrient deficiencies by laboratory examination
of serum or plasma: iron, vitamin B12, zinc and folic
acid. Subjects with pathological testing according to
local laboratory standards were regarded as micronu-
trient deficient. Subjects with an iron/total iron-binding
capacity ratio <0.16 were considered to be iron deficient
[27]. Patients with pathological testing for more than
Andréasson et al. Arthritis Research & Therapy 2014, 16:R46 Page 3 of 9
http://arthritis-research.com/content/16/1/R46one of the aforementioned micronutrients were cate-
gorised as having multiple deficiencies.
Ethics
The study was approved by the Lund University Ethics
Committee, Lund, Sweden. All patients and healthy vo-
lunteers gave their written permission according to the
Declaration of Helsinki to be included in the study.
Statistics
As previously described, the distribution of the log-
transformed FC values allowed parametric statistics [3]. Stu-
dent’s t-test, 1-way analysis of variance and Pearson correl-
ation coefficient could thus be used and comparative data are
thus presented in geometric means. Paired t-test was used
when comparing repeated FC measurements in the same pa-
tients. Consistency was measured with intraclass correlation
(ICC) and kappa statistics (κ). FC values <30 μg/g were ap-
proximated as 20 μg/g in all analyses. When calculating the
ICC, separate data are presented for which FC values <30 μg/
g are excluded. Median and interquartile range (IQR) was
used for descriptive data. A two-sided P-value of 0.05 was
considered significant and 95% confidence intervals (CI) given
when possible. Because of the interdependence between differ-
ent variables analysed in this study, we chose not to use Bon-
ferroni correction. All analyses were made using IBM SPSS
Statistics version 20 (IBM Corporation, Somers, NY, USA).
Results
In total, 93 SSc patients had FC measured at least twice dur-
ing the study period. Of these patients, FC had been mea-
sured three times in 57 patients and at least four times in 27
patients. The main characteristics of the patients involved in
this study are presented in Tables 1 and 2.
FC correlates with objective variables of GI disease in SSc
Eighty-three subjects had conclusive cineradiographies.
Of these, patients with a pathological investigation had
higher levels of FC (geometric mean 119 versus 53 μg/g,
P = 0.010), Figure 1. In eight cases RH and AS did not
agree if the investigation was pathological or not, and in
another five cases RH and AS did not agree on the
severity of a pathological examination. Out of thirteen





Systemic sclerosis (n = 93) 62 (51 to 70) 7
Primary Sjögren’s syndrome (n = 44) 61 (55 to 68) 4
Rheumatoid arthritis (n = 24) 66 (55 to 69) 2
Healthy controls (n = 21) 56 (47 to 58) 1
DAS28-CRP(3), Disease Activity Score 28 based on CRP and 3 variables; ESSDAI, EULpathological FC levels. Among the remaining 70 patients
with pathological cineradiographies, 56 patients had
pathological FC levels. Patients with micronutrient de-
ficiency had higher FC values compared to micronu-
trient sufficient patients (geometric mean 118 versus 50,
P = 0.001), Figure 2.
FC shows a low degree of intra-individual variation over
time in SSc
The median (IQR) time span between the first (FC1)
and the second (FC2) stool delivery was 369 (318 to
725) days. We saw only limited variation in FC over time
(Figure 3) and the reliability of FC to classify patients as
having normal or pathological FC levels was substantial,
κ = 0.64 (95% CI: 0.56 to 0.73, n = 93) [28].
The consistency between FC1 and FC2 was good both
when all patients were included, ICC = 0.69 (95% CI: 0.57
to 0.78), and when cases <30 μg/g were excluded, ICC =
0.62 (95% CI: 0.46 to 0.74) [29]. We saw no tendency of
FC to increase or decrease with time as FC1 and FC2
levels were similar (geometric mean 130 versus 125 μg/g,
P = 0.625). This was also true for patients with disease
duration less than 400 days (n = 15) at time point 1, where
no increase in FC could be seen over a median (IQR) time
period of 358 (229 to 385) days (geometric mean 83 versus
96 μg/g, P = 0.437). Notably, however, 11/15 of these early
patients had pathological FC levels already at baseline.
The consistency and reliability of FC was not superior
in patients with a short timespan compared to patients
with a long timespan between FC1 and FC2 (data not
shown).
A separate analysis of patients who had FC measured
at least three times further indicated that patients with
normal, pathological or substantially elevated FC levels
were also likely to show a similar FC result upon re-
peated testing (Table 3).
Initiation or cessation of immunosuppression is not
associated with a change in FC
During the study, eight patients had FC measured both
before and after initiation of immunosuppressive therapy.
Median (IQR) disease duration at FC1 was 295 (156 to
575) days and the second FC was delivered 339 (190 to






7 (83) 110 (42 to 210) NA
3 (98) 41 (<30 to 118) 7 (1 to 10)
0 (83) 43 (<30 to 93) 3.1 (2.1 to 3.9)
7 (81) <30 (<30 to 56) NA
AR Sjögren’s Disease Activity Index; IQR, interquartile range; NA, not applicable.
Table 2 Characteristics of SSc patients
Characteristic Number (%)
Diffuse: limited skin involvement 20:73 (22:78)
Anti-centromere antibodies 30 (32)
Anti-topoisomerase antibodies 22 (24)
Anti-RNA polymerase III antibodies 3 (3)
Pathological cineradiography 70 (75)
Immunosuppressive therapy 36 (39)
Median (IQR)
Disease duration (years) 7 (2 to 13)
IQR: interquartile range.
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sitis, arthritis, serositis or any combination of these
manifestations, but not because of gastrointestinal dis-
ease. Four patients started immunosuppression with
azathioprine, three with mycophenolate mofetil and one
with cyclophosphamide.
FC was not different before compared to after initia-
tion of immunosuppressive therapy (geometric mean 41
versus 71 μg/g, P = 0.243).
During the study, 15 patients delivered FC both before
and after cessation of immunosuppressive therapy. The
majority of the patients had been prescribed immunosup-
pressants because of interstitial lung disease and no one
because of gastrointestinal disease. A majority of the pa-
tients (9/15) had been prescribed mycophenolate mofetil,
four had been prescribed azathioprine and two cyclophos-

















Figure 1 In systemic sclerosis, faecal calprotectin is associated with p
levels in systemic sclerosis patients with different degrees of pathological c
logarithmic scale on the y-axis.cessation of immunosuppression (geometric mean 112
versus 130 μg/g, P = 0.380).
Twenty-six SSc subjects were taking glucocorticoids at
FC1; no relationship between FC and glucocorticoid in-
take was noted (r = 0.14, P = 0.182).
FC is higher in SSc compared to pSS, RA and healthy
controls
FC was measured in patients with pSS (n = 44) and RA
(n = 24), and healthy controls (n = 21) (Table 1 and
Figure 4). FC was significantly higher in SSc compared
to any of the three other groups (P < 0.005 for each
comparison).
Of note, patients with pSS had significantly higher FC
values than healthy controls (geometric mean 57 versus
34 μg/g, P = 0.019). Furthermore, FC correlated with
ESSDAI in these patients (r = 0.52, P < 0.001). Subgroup
analysis of the different ESSDAI-components did not in-
dicate any specific domain score of the ESSDAI to be
solely responsible for this correlation. There was a weak
correlation between FC and erythrocyte sedimentation
rate (r = 0.31, P = 0.048), but no correlation between FC
and immunoglobulin G (IgG) (r = 0.04, P = 0.785). There
was no significant difference in FC between users and
non-users of NSAIDs or PPI (geometric mean 43 versus
68 μg/g, P = 0.108 and 69 versus 52 μg/g, P = 0.399, re-
spectively). Finally, among the pSS patients, FC did not
correlate with glucocorticoid intake (r = 0.19, P = 0.211).
In RA, FC was not significantly higher than in healthy
controls (geometric mean 52 versus 34 μg/g, P = 0.069)
and did not correlate with disease activity measured asological      Severely pathological
athological cineradiograhy. Individual and median faecal calprotectin























Figure 2 In systemic sclerosis, faecal calprotectin is associated with micronutrient deficiency. Individual and median faecal calprotectin
levels in systemic sclerosis patients with different degrees of micronutrient deficiency. 1-way analysis of variance, P = 0.005. Please note the logarithmic
scale on the y-axis. Patients were subject to analysis of the following micronutrient deficiencies by laboratory examination of serum or plasma: iron,
vitamin B12, zinc and folic acid. Subjects with pathological testing according to local laboratory standards were regarded as micronutrient deficient.



















Figure 3 Repeated testing of faecal calprotectin in systemic sclerosis. Faecal calprotectin at time point 2 as a function of faecal calprotectin
at time point 1 in 93 SSc patients. ICC = 0.69 (95% CI: 0.57 to 0.78). Please note the logarithmic scale on the x- and y-axis. CI, confidence interval;
ICC, intra class correlation.
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Table 3 Faecal calprotectin is stable over time in systemic sclerosis
Typical FC level
Variability of FC over time Normal Elevated Substantially elevated All patients, n (%)
FC < 50, n FC = 50-200, n FC >200, n
Cohort A, n = 57
Solida 6 7 6 19 (33)
Stableb 3 18 12 33 (58)
Inconclusivec 0 4 1 5 (9)
All patients 9 29 19 57 (100)
Cohort B, n = 28
Solida 4 1 2 7 (25)
Stableb 1 7 6 14 (50)
Inconclusivec 0 4 3 7 (25)
All patients 5 12 11 28 (100)
aAll FC measures fall into the same category; ball FC measures fall into the same category except 1 that is 1 step lower/higher; cthe FC measures show higher
variability than above. Stool samples were delivered for analysis of FC at three (Cohort A) or four (Cohort B) time points and FC was categorised as solida, stableb
or inconclusivec. FC: faecal calprotectin measured in μg/g.
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cant correlation between FC and glucocorticoid intake
(r = 0.66, P < 0.001), in contrast to patients with pSS or
SSc. RA subjects taking NSAIDs or PPI did not have
significantly higher FC levels compared to non-users
(geometric mean 55 versus 46 μg/g, P = 0.666 and 62

















Figure 4 Faecal calprotectin in different patient groups. Individual and
(SSc) n = 93, primary Sjögren’s syndrome (pSS) n = 44, rheumatoid arthritis
scale on the y-axis.Discussion
In the present study we have assessed repeated testing of
FC as a biomarker for SSc GI disease in 93 patients
showing low variability over time. In order to be of cli-
nical value, a biomarker should be objective, feasible,
show construct and face validity, be stable over time but
also sensitive to change if disease severity or activity isRA Healthy
controls
median levels of faecal calprotectin in patients with systemic sclerosis
(RA) n = 24 and healthy controls n = 21. Please note the logarithmic
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of its wide spread use in gastroenterology is readily avail-
able in the clinic.
In this study we confirm our earlier results showing
significant correlations between FC and objective signs
of SSc GI disease as determined by cineradiography and
testing for micronutrient deficiency. These data imply
construct validity of FC for SSc GI disease.
FC is measured in stool samples originating from the
GI tract which is the very organ system implicated in
SSc GI disease suggesting face validity.
The intra-individual variability of FC has been studied
in a cohort of patients with quiescent Crohn’s disease
with a similar distribution of FC as our SSc subjects
[31]. These patients were tested on consecutive days and
the ICC and κ statistic were thus projected mainly to
reflect methodological rather than biological variation.
The ICC and κ statistic in that study (0.84 and 0.648)
are similar to our results, 0.62 and 0.64, respectively.
These results indicate not only substantial consistency of
repeated FC testing in SSc, but also that the intra-
individual variation of FC in SSc is low even when tes-
ting is separated by longer time periods.
FC has been shown to be a feasible test in IBD [32].
All patients in the present study were examined at least
twice, 57 patients three times, and 28 patients four
times. The patients were motivated to deliver stool sam-
ples and our experience during this study is that mul-
tiple testing of FC in this in-hospital setting is as feasible
in SSc, as has been shown in IBD.
To date, no drug has been shown to modulate the basic
mechanisms behind GI manifestations of SSc [7,10]. The
poor response of SSc GI disease to immunosuppression
was reflected by FC, as we could not identify any asso-
ciation between FC and initiation or cessation of immuno-
suppressive therapy. Both the behaviour of FC and the
clinical GI picture are thus different in SSc compared to
IBD in relation to immunosuppressants. This is a crucial
requisite if FC is to function as a biomarker in SSc.
While we show that FC is stable over time, we have
yet to show if FC is sensitive to change. Our findings
may suggest that any drug affecting FC levels in SSc may
actually modulate the GI tract in a unique way and
could thus have potential as a drug that suppresses SSc
GI disease.
Calprotectin levels in serum and joint fluid in RA and
osteoarthritis have attracted considerable interest, but
less is known about faecal levels of calprotectin in
rheumatic diseases [33,34]. An initial report on the
methodology of FC testing in 1992 indicated increased
levels of FC in RA patients [15]. FC has also been stu-
died in patients with ankylosing spondylitis, of whom,
interestingly, a majority presented pathological FC tes-
ting [35,36].Our data indicate that pathological FC testing is more
common in SSc compared to pSS and RA. Still, FC
levels were higher in pSS compared to healthy controls,
and FC is not specific for SSc in an unselected rheum-
atological setting. In RA, we identified a significant, dose
dependent association between FC and glucocorticoid
usage. Associations between FC and NSAID usage have
been reported, but to our knowledge not studied in pa-
tients with RA or pSS before. Similar to our previous re-
port in SSc, we did not identify any association between
FC and NSAIDs that can explain our findings in pSS
and RA [3,35,37]. These findings need further investiga-
tion and question the generalisability of proposed cut-off
levels of FC for patients with chronic diseases under dif-
ferent medical therapies.
pSS is a systemic autoimmune disease characterised by
inflammation of the exocrine glands which also can in-
volve the GI tract. The pathogenesis behind GI disease in
pSS has been suggested to be quite different compared to
SSc. While autonomic nervous dysfunction [38] and GI
dysmotility [39] are common in both diseases no inflam-
matory component similar to SSc has been described [40].
Our findings support the notion that the inflammatory
component of SSc GI pathology is different compared to
pSS.
Several organ manifestations of SSc change in both in-
tensity and characteristics over time, most notably sclero-
derma of the skin, lung fibrosis and pulmonary arterial
hypertension. We also identified pathological levels of FC
in patients with early SSc. GI manifestations of SSc are re-
ported to be common in both early and late disease. Our
findings support this notion but do indicate that a possible
inflammatory component could also be prevalent in late
disease [41]. It can be speculated that pathological FC tes-
ting in early SSc may reflect the debut of GI involvement
and thus predict later clinical manifestations of SSc GI
disease. This remains to be studied further.
Some weaknesses of this study deserve to be mentioned.
Several FC ELISAs are now available on the market. While
little variation is seen within different laboratories, sub-
stantial variation has been documented between different
laboratories in general and between different ELISAs in
particular [42]. The FC measurements in this study were
all done at the same laboratory using a monoclonal anti-
body in an ELISA that recently was shown to be superior,
both in terms of specificity and sensitivity, in correctly
identifying GI pathology, compared to other ELISAs [43].
The time period between the FC1 and FC2 was not
standardised. This is in contrast to a recent study of FC in
IBD, and warrants caution when interpreting our data
[31]. Furthermore we cannot rule out the possibility of a
certain selection bias since only SSc patients subject to re-
peated in-hospital care were recruited to the study. Finally,
SSc is a heterogeneous disease. Several GI manifestations
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rule out the possibility that only a limited number of GI
manifestations contribute to FC elevation in SSc. Accor-
dingly, we do not know the origin of FC in SSc. Increased
levels of FC have been described in diseases affecting both
the upper and lower GI tract [16]. Autopsy and biopsy
studies have shown deposition of inflammatory cells, in-
cluding monocytes and neutrophils, in many segments of
the GI tract in SSc [40,44]. It can be hypothesised that FC
originates from such infiltrates. However, further studies
are needed to investigate the exact pathological mecha-
nisms behind increased excretion of FC in SSc.
Conclusions
FC is a non-invasive biomarker for GI disease in SSc with
only limited variation upon repeated testing. FC is higher
in SSc compared to RA, pSS and healthy controls. Even
though further studies are needed to determine the exact
mechanisms behind pathological FC testing in SSc, FC is a
promising tool for assessing novel drugs targeting the GI
tract in SSc.
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